AGP Executive Report

AI & Research Links: Nagoya University researchers visited Ethiopia’s Artificial Intelligence Institute to explore cooperation across areas including health, agriculture, law enforcement, and language tech for machine tools. Public Health Alert: Nepal confirmed 131 Japanese encephalitis cases in 2026 so far, with 28 deaths; authorities say 87% of patients were unvaccinated and are expanding vaccination campaigns plus mosquito-bite prevention in affected districts. Clinical Pipeline Updates: BioMarin shared five-year Phase 3/extension results for POMBILITI + OPFOLDA in late-onset Pompe disease, reporting durable motor outcomes and pulmonary stabilization through year five. Dermatology Drug News: Pfizer reported Phase 3 data showing LITFULO (ritlecitinib) significantly improved facial and total-body repigmentation in nonsegmental vitiligo, with plans to submit to regulators. Healthcare Tech in Japan: A Tokyo startup, AIBORN, secured funding from Medical Data Vision for “Katanashi,” an AI tool aimed at turning doctor-patient speech into structured medical records to cut administrative burden. Health & Weather: Tokyo’s record 35-day rain streak is being linked by doctors to headaches and dizziness, with knock-on effects including higher vegetable prices and mental strain.

Japan Flu Watch: Japan’s Health Ministry says the average number of flu cases per medical institution has topped the critical 1.0 threshold across all 47 prefectures, with the latest week averaging 7.17 patients per clinic; Okinawa hit 42.50, and officials urge basic prevention like handwashing and covering coughs. Cancer Care Update: Korean specialists highlight a shift in stage 2–3 stomach cancer toward chemotherapy before and after surgery, plus immunotherapy to reduce recurrence risk. Kidney Warning Signs: A nephrology expert stresses that repeated blood or protein in urine—even without symptoms—can point to glomerular damage and may require prompt specialist testing to prevent long-term decline. Longevity Habits: A “Blue Zones” explainer points to everyday natural movement and simple whole-food diets as common threads behind healthier centenarian life, using examples including Okinawa. Hospital Tech & Comfort: Japan’s entertainment robots are diversifying with AI—some aimed at emotional support for patients (including a robot used at Jikei University Hospital) and others marketed as companion or interactive devices. Wellbeing App Launch: Thirty2give’s “Is It Well” app is set to roll out in Brazil, Japan, Kenya, and Zambia, sending encouragement prompts to a user’s chosen support circle when they answer “no.” Ortho Access: Aspirus says Dr. Robert Blotter has joined its orthopedic team to expand specialized musculoskeletal care across Michigan’s Upper Peninsula.

Japan Health Policy: Japan begins talks on free childbirth, a move that could reshape maternal care access and costs for families. Public Health & Preparedness: Japan is also looking to keep domestic vaccine production capacity built during COVID-19, seeking major budget support to avoid overreliance on overseas suppliers in the next crisis. Healthcare Tech & Regulation: The government is pushing an AI transformation plan with a year-end deadline, aiming to speed adoption across industries including medicine while easing regulations. Medical Innovation (Japan-linked): Novocure’s Optune Pax wins Japan approval for unresectable locally advanced pancreatic cancer, adding to the growing list of device-based oncology options. Clinical Research Collaboration: Daiichi Sankyo and AstraZeneca launch a trial collaboration with Summit Therapeutics to test Datroway plus ivonescimab across multiple tumor types, starting with phase 3 in first-line triple-negative breast cancer. Global Health (Not Japan, but health-relevant): West Sepik in Papua New Guinea rolls out mass drug administration and immunization targeting neglected tropical diseases.

Japan Health Tech & Care Access: A lightly staffed off-grid clinic is planned in western Izu (Numazu/Izu area), aiming for solar-and-rainwater self-sufficiency and offering online consultations when doctors aren’t on site, with diagnostic tools like throat imaging and devices to analyze hair and urine. Japanese Medical Innovation: Japan’s Fukuoka Kieikai Hospital plans an advanced brain radiosurgery program using ZAP-X gyroscopic radiosurgery. Japan Clinical Breakthrough: Reports say a Japanese hospital has performed the first surgery using heart muscle stem cells, marking a major step for regenerative medicine. Pharma Watch (Japan-relevant global pipeline): Roche’s Susvimo was approved by the European Commission for neovascular age-related macular degeneration, adding a continuous-delivery implant option to frequent eye injections. Policy & Workforce (health-adjacent): Hawaiʻi recognized workforce development “hero” awardees, including a licensed medical social worker at a comprehensive health center, highlighting talent pipelines that support care delivery.

Drug Approval Watch: The US FDA expanded Bristol Myers Squibb’s Camzyos (mavacamten) approval to include symptomatic obstructive hypertrophic cardiomyopathy in pediatric patients weighing at least 30kg, based on the SCOUT-HCM trial, with no new safety concerns beyond the known adult profile. Ophthalmology & Devices: SpyGlass Pharma agreed to buy Advanced Vision Science (AVS) for about $13m to secure scalable intraocular lens manufacturing capacity for its Phase 3 BIM-IOL System and expand lens options in Japan. Clinical Pipeline Updates: Belite Bio said it will present new inherited retinal disease data for tinlarebant at Innovate Retina and the American Academy of Ophthalmology meeting. Tech + Health Ops: Microsoft reported a major Azure connectivity disruption affecting hybrid connections across 18 regions, a reminder of how fragile healthcare IT links can be during cloud maintenance. Public Health & Aging: Japan’s health ministry reported a record 107,677 people aged 100+ (88% women), highlighting the growing need for social security support for healthy longevity. Healthcare Administration Error: Osaka-area Sakai city admitted a staff mistake that marked a living spouse as dead, temporarily stripping 75+ medical coverage eligibility before correcting the resident record.

World-First Regenerative Medicine in Japan: A Japanese hospital performed the world’s first surgery using commercially available heart muscle stem cell sheets derived from iPS cells, aiming to improve quality of life for a woman in her 50s with ischemic heart disease after conditional approval earlier this year. Aging & Care in Osaka: In Nishinari’s Kamagasaki area, an elderly support group helps people with no family arrange funerals in advance, tackling “dying alone” with community care. Japan Policy Changes From October: New rules will require companies and local governments to act against customer harassment, while other October changes include higher immigration-related fees and the end of the “¥1.06 million” social insurance enrollment threshold. Cardiology Drug Update (US): The FDA expanded CAMZYOS (mavacamten) for symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients, signaling broader treatment options. Clinical Trial Push (Japan-linked pharma): Taiho Oncology reported positive Phase 3 AZTOUND topline results for an all-oral azacitidine/cedazuridine regimen in MDS/CMML, with plans to seek US approval. Public Health Tech: A Japan hospital and researchers are also advancing faster cancer detection tools, including laser-based colorectal biomarker detection in minutes. Community Nutrition: An east Japan city will add “GariGarikun” ice treats to school lunches to help students beat lingering heat.

Regenerative Medicine Breakthrough: Osaka Keisatsu Hospital carried out the world’s first surgery using sheets of heart muscle cells made from iPS-derived regenerative products, with the patient in stable condition after a ~50-minute procedure; the therapy (RiHeart) was conditionally approved in March 2026 and is now covered by public insurance starting Sept. 1. Public Health & Wellness: A study of major marathons found air pollution (especially nitrogen dioxide) can slow runners by several minutes, adding to the growing case for cleaner race-day environments. Healthcare Tech & Data: Flatiron Health expanded global real-world datasets with AI-powered breast cancer and NSCLC data for the UK, Germany, and Japan, aiming to support research and care decisions. Animal Welfare Oversight: Japan launched its first nationwide survey of animal cafes to assess welfare, hygiene, wildlife trade risks, and potential public health concerns. Dermatology Pipeline Update: Verrica Pharmaceuticals said new pooled Phase 3 analysis for YCANTH (VP-102) showed complete clearance of molluscum contagiosum about four times faster than vehicle, with more patients clearing lesions across time points. Lifestyle & Prevention: Research highlights that slow jogging can deliver immediate mood and brain benefits, reinforcing “less intense” exercise as a practical health strategy.

Drug Tariffs & Access: The U.S. expands drug tariffs to more branded makers, but keeps major exemptions for generics/biosimilars and categories like orphan drugs, cell/gene therapies, and some oncology and fertility products—raising questions about R&D pressure for smaller firms. Aging & Brain Health: A small 12-week MIND diet trial in older adults with mild cognitive impairment reports gains in cognition and daily functioning, though researchers stress it doesn’t prove dementia prevention. Japan Health Tech & Policy: Japan’s used bookstores boom is shadowed by fears that bulk purchases are being used for AI scanning and shredding. Wearables in Care: South Korean wearable ECG makers push into the U.S., betting long-term monitoring demand will outpace limits from Japan’s reimbursement rates. Clinical Pipeline (Japan-linked): Dyne Therapeutics reports additional one-year Phase 1/2 ACHIEVE data for myotonic dystrophy type 1, with next steps aimed at potential accelerated approval. Wellness & Lifestyle: Practical guidance on recovering from stress and burnout highlights how constant stress can harm sleep and thinking. Environment & Health: Researchers in Japan report “plasticoral” fused to coral rubble, flagging new pathways for microplastics and possible chemical leaching.

Clinical Breakthrough (Japan): Japan’s first public insurance-covered iPS heart sheet surgery has been performed, using a cardiac muscle sheet derived from induced pluripotent stem cells (RiHeart) developed by Cuorips Inc—an early milestone for regenerative cardiac care. Pharma Strategy (Japan): Asahi Kasei will unify its global pharmaceutical units under the Asahi Kasei Therapeutics brand, signaling a push into specialty areas like immunology, nephrology, transplantation and infectious diseases. Neuromuscular Trials (Global): New Phase 3 and long-term updates highlight momentum in rare neuromuscular disease research, including zeleciment basivarsen for myotonic dystrophy type 1 and telitacicept response durability in generalized myasthenia gravis. Oncology & GI Pipeline (Global): AstraZeneca’s $2B investment into Summit Therapeutics supports ivonescimab development, while Phathom starts a registrational Phase 3 study of vonoprazan for as-needed non-erosive GERD. Public Health (Asia): Taiwan reports 130,000+ flu-related visits last week, with activity expected to ease in mid-October. Health System/Access (Japan): A new insurance-backed iPS procedure adds to the broader shift toward making advanced therapies available through coverage.

Wellness & Care: Pasona Natureverse has opened on Awaji Island with 57 rooms and a thalassotherapy-led program built on Japan’s “mibyo” idea of “pre-illness,” using personalized nutrition, exercise and sleep plans plus on-site and partner-clinic medical support. Clinical Research & Drugs: HUTCHMED says AstraZeneca has filed a US NDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) for MET-overexpressing/amplified EGFR-TKI–progressed lung cancer, backed by the SAFFRON Phase III trial showing improved progression-free and overall survival. Eye Health Pipeline: Belite Bio will present new data at Euretina in Vienna, including Phase 3 DRAGON results for tinlarebant in adolescent Stargardt disease. Cardiovascular Evidence: A meta-analysis reports PPV23 vaccination was not clearly linked to lower acute coronary syndrome, stroke, or all-cause mortality. Menopause & Heart Risk: A JAMA Internal Medicine target-trial emulation finds cardiovascular risk was lower when menopausal hormone therapy starts in perimenopause/early postmenopause, supporting a “timing” effect. Digital Privacy for Families: Memori Baby, an ad-free baby tracker and private family photo album from Fukuoka, launches on the App Store with on-device processing and optional end-to-end encryption. Public Health Policy: The US will apply zero ad valorem tariffs to certain rare-disease and advanced therapies imported from India and 19 other countries, including Japan.

AI Skin Cancer Tech: DermaSensor launched in Germany via ContraCare’s DERMALYTICA, following a Class IIb CE Mark and an NHS collaboration in the UK—aimed at dermatologists and lesion-risk detection. Clinical Pipeline in Japan: MediciNova reported topline Phase 2 results for MN-001 (tipelukast) in NAFLD with type 2 diabetes, showing triglyceride improvements and generally favorable safety. Diabetes Innovation: Lilly’s once-weekly insulin Onswik and related updates keep momentum in Japan’s diabetes landscape, with regulators also approving new insulin options for adults with type 2 diabetes. Emergency Care Case Study: Japanese doctors described a rare pneumomediastinum case after a man swallowed a large steamed meat bun without chewing, highlighting a potential “ask-first” trigger for emergency teams. Public Health & Environment: Indonesia’s wildfire haze continues to worsen respiratory illness risks, while South Korea reported rising influenza and COVID-19 after holiday travel—both underscoring near-term strain on healthcare systems. Workplace Health: A global HR explainer warned that workers’ compensation systems vary widely by country, often leading teams to mis-handle injury claims.

Heated Tobacco & Hypertension: A nationwide Japanese cohort study reports higher incident hypertension risk among current heated tobacco users, while noting the relationship is more complex than a simple cause-and-effect story. Suicide Prevention in Japan: New data show emergency ambulance transports for self-harm and attempted suicide are rising in Japan, especially among younger people and women, with drug overdoses the most common method. Mental Health Response: A U.S. military suicide-prevention piece stresses community-wide responsibility and points to on-base behavioral health and chaplain support as key first steps. Cancer Care & Trials: Hutchmed has started a global Phase Ia trial of HMPL-A830, an antibody-targeted KRAS-EGFR conjugate, in patients with advanced solid tumors. Diabetes Treatment Watch: FDA panel coverage highlights ongoing scrutiny and approvals around once-weekly insulin options, while separate reporting notes experts say GLP-1 vision-loss claims may be hard to prove in court. Aging & Demographics: Japan’s fertility divide is getting sharper, with eastern prefectures lagging behind the west, and the number of people aged 100+ hitting an all-time high. Healthcare Funding: Ukraine says it will protect full, timely funding for pensions and doctors’ and teachers’ salaries even as other spending may be paused until international support arrives.

Aging Milestone: Japan’s centenarian population hit a record 107,677, with 88% women, as the health ministry points to better living conditions, diet and nutrition, plus medical advances. Sports & Health Logistics: Asian Games organisers in Aichi-Nagoya said they were caught off guard by complaints about cramped container-style athlete housing and promised more comfortable stays for the final week. Medical Tech Showcase: TamaBio will present its synthetic biomembrane platform at the American College of Surgeons Clinical Congress in Washington, aiming to tackle implant issues like adhesion, calcification, infection and fluid leakage. Longevity & Care Focus: A Japanese study reports emergency abdominal surgery can be feasible for patients over 85, adding practical options for older patients in urgent settings. Public Health Nutrition: Diet experts weigh in on sardines—nutrient-rich and convenient—but note they’re not ideal for everyone, depending on individual needs and intake. Healthcare Business Watch: Fortis Healthcare says it is a “complete stranger” to the Daiichi Sankyo–Singh Brothers dispute after the Supreme Court cleared a forensic audit path. Wellness Trend: Japan is tightening rules as regenerative medicine treatments spread, reflecting growing oversight pressure as the field expands.

Sports Medicine & Safety: A WTA player, Tatiana Prozorova, was ruled unfit after a ball hit her face during doubles, triggering concussion protocol and forcing her out of a Singapore Open semifinal—another reminder of how quickly head injuries can sideline athletes. Healthcare Policy Roundup: The HCPFive highlights major FDA moves this week, including priority reviews and insulin approvals, plus label updates for pulmonary arterial hypertension and other conditions—useful for clinicians tracking regulatory momentum. Clinical Research: New studies span dry eye treatment trials (TRPV1-focused approaches), needlestick injury risk among healthcare workers, and multiple oncology-focused nanoparticle and drug-delivery papers, reflecting continued push for faster, targeted therapies. Japan Health & Care Access: Japan’s Defense Ministry plans a startup-friendly contract system for unmanned aerial vehicles, aiming to speed innovation—relevant to future medical logistics and base operations. Public Health & Community: Japan’s centenarian milestone (100,000+) and ongoing aging-related coverage underscore the growing need for prevention, support, and long-term care planning. Injury & Emergency Care: A Gifu man was arrested after allegedly throwing his two daughters from a sixth-floor balcony; both children were conscious and taken to hospital, spotlighting the stakes for rapid emergency response.

Aging & Caregiving: Japan is seeing “grandchild leave” spread as working grandparents help with child care, with companies and local governments offering paid leave to support families amid longer working lives. Local Health Support: Hitachiota, Ibaraki will start paying residents via digital local currency for helping elderly or disabled neighbors take out household waste—aiming to reduce daily burdens for people who struggle with garbage disposal. Public Health Research: A review of millions of people reports COVID-19 is linked with a higher risk of developing new autoimmune diseases afterward, urging clinicians to stay alert to post-acute autoimmune presentations. Animal Health & Climate: Tokyo’s Tama Zoo says three lionesses died during a record heat wave, with necropsies pointing to dehydration and multiple organ failure. Cancer Screening (Japan-linked): A Canadian doctor is sharing training from Japan on adding a quick hypopharynx check during upper endoscopy to catch throat cancers earlier. Drug Development: Daiichi Sankyo and Merck voluntarily withdrew a U.S. accelerated-approval bid for ifinatamab deruxtecan in extensive-stage small cell lung cancer, while a phase 3 trial continues.

FDA Review Watch: The FDA has granted priority review for perioperative durvalumab (Imfinzi) plus enfortumab vedotin (Padcev) in muscle-invasive bladder cancer patients who can’t take cisplatin, based on the VOLGA trial, with an action date targeted for Q4 2026. Cancer Pipeline: The FDA also started a speedy review of Imfinzi in bladder cancer, underscoring how quickly regulators are moving on oncology combinations. Japan Health Research: Oita University will open Japan’s first university research hub focused on the medical, wellness and cosmetic benefits of hot-spring bathing, aiming to support longer healthy life expectancy and local wellness tourism. Clinical Long-Term Data: Legend Biotech released 5-year follow-up results for CARVYKTI in relapsed/refractory multiple myeloma, reporting 50% of patients alive and progression-free after a single infusion. Public Health & Safety: A woman died after becoming unresponsive during a guided wreck dive on USS Emmons off Okinawa; authorities are investigating the circumstances. Community & Aging: Malaysia is debating pension reform to prevent old-age poverty as populations age, highlighting the broader regional pressure on health and welfare systems.